It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
APGE’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
APGE’s TA Score shows that 6 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).
APGE (@Biotechnology) experienced а +2.53% price change this week, while SYRE (@Biotechnology) price change was +2.01% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +14.28%, and the average quarterly price growth was +9.89%.
APGE is expected to report earnings on Nov 11, 2024.
SYRE is expected to report earnings on Feb 27, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
APGE | SYRE | APGE / SYRE | |
Capitalization | 3.19B | 1.79B | 179% |
EBITDA | -134.74M | -172.92M | 78% |
Gain YTD | 101.503 | 63.058 | 161% |
P/E Ratio | N/A | 3.22 | - |
Revenue | 0 | 0 | - |
Total Cash | 676M | 426M | 159% |
Total Debt | 4.08M | 0 | - |
SYRE | ||
---|---|---|
OUTLOOK RATING 1..100 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 37 | |
P/E GROWTH RATING 1..100 | 29 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
APGE | SYRE | |
---|---|---|
RSI ODDS (%) | N/A | 2 days ago83% |
Stochastic ODDS (%) | 2 days ago83% | 2 days ago85% |
Momentum ODDS (%) | 2 days ago73% | 2 days ago84% |
MACD ODDS (%) | 2 days ago80% | 2 days ago74% |
TrendWeek ODDS (%) | 2 days ago86% | 2 days ago83% |
TrendMonth ODDS (%) | 2 days ago82% | 2 days ago83% |
Advances ODDS (%) | 2 days ago85% | 2 days ago84% |
Declines ODDS (%) | 6 days ago71% | 8 days ago90% |
BollingerBands ODDS (%) | 2 days ago90% | 2 days ago90% |
Aroon ODDS (%) | 2 days ago89% | N/A |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
RERGX | 58.24 | 0.13 | +0.22% |
American Funds Europacific Growth R6 | |||
MSECX | 13.68 | 0.01 | +0.07% |
Morgan Stanley Inst International Eq C | |||
IHOAX | 18.80 | N/A | N/A |
Hartford International Opportunities A | |||
VGSAX | 36.00 | N/A | N/A |
Virtus Duff & Phelps Glb Rl Estt Secs A | |||
BOSCX | 19.44 | -0.06 | -0.31% |
BNY Mellon Sm Cp Val C |
A.I.dvisor indicates that over the last year, APGE has been loosely correlated with SYRE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if APGE jumps, then SYRE could also see price increases.
Ticker / NAME | Correlation To APGE | 1D Price Change % | ||
---|---|---|---|---|
APGE | 100% | +3.32% | ||
SYRE - APGE | 39% Loosely correlated | +3.27% | ||
BHVN - APGE | 38% Loosely correlated | -1.65% | ||
ALLO - APGE | 38% Loosely correlated | +10.29% | ||
ACLX - APGE | 37% Loosely correlated | +0.31% | ||
SRRK - APGE | 34% Loosely correlated | -2.64% | ||
More |
A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with SNPX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then SNPX could also see price increases.
Ticker / NAME | Correlation To SYRE | 1D Price Change % | ||
---|---|---|---|---|
SYRE | 100% | +3.27% | ||
SNPX - SYRE | 47% Loosely correlated | -3.72% | ||
PMN - SYRE | 44% Loosely correlated | -6.09% | ||
GOSS - SYRE | 41% Loosely correlated | +1.44% | ||
MLTX - SYRE | 41% Loosely correlated | -0.77% | ||
TCRX - SYRE | 39% Loosely correlated | +2.63% | ||
More |